TAMPA, Fla.--(BUSINESS WIRE)--Intezyne today announced it has received notification the European Patent Office intends to grant a patent covering a key element of Intezyne’s breakthrough drug delivery technology, the IVECT™ Method. At the core of this technology is the IVECT micelle, a proprietary, polymeric nanoparticle designed to encapsulate and deliver best-in-class therapeutics, while limiting exposure to healthy tissues. The IVECT Method is already covered by seven additional patents both in the United States and worldwide. This wide-ranging, European patent covers technology that allows greater flexibility and versatility of the IVECT micelle, particularly with respect to the amount of hydrophobic material that can be encapsulated into this drug delivery vehicle, further bolstering Intezyne’s intellectual property portfolio.
